Keyphrases
Chimeric Antigen Receptor T Cells (CAR-T)
100%
T Cell Depletion
30%
T Cells
27%
Chimeric Antigen Receptor T-cell Therapy
27%
Adoptive Cell Therapy
19%
T Cell Targeting
16%
B-cell Malignancies
16%
Engineered T Cells
16%
CD19
16%
Acute Lymphoblastic Leukemia
14%
Chimeric Antigen Receptor Therapy
14%
Clinical Trials
14%
T Cell Activation
13%
Cell Therapy
11%
Neuroblastoma
11%
Tumor
10%
4-1BB
9%
Resistance Mechanisms
9%
Co-stimulatory Domain
9%
CD22
9%
Adoptive Immunotherapy
9%
Xenograft Model
9%
Antigen-independent
9%
Highly Active
9%
Leukemia
8%
Cancer Immunotherapy
8%
Hematological Malignancies
7%
CART19
7%
Solid Tumors
7%
Autologous T Cell
7%
Culture Method
7%
Ovarian Cancer
7%
Chronic Lymphocytic Leukemia
7%
Pediatric Malignancy
7%
Non-Hodgkin Lymphoma
7%
Early Memories
6%
Memory Phenotype
6%
Hematopoietic Cell Transplantation
6%
CAR Therapy
5%
Clinical Application
5%
Immune Response
5%
Response Rate
5%
Antigen-specific
5%
High Affinity
5%
CD19 chimeric Antigen Receptor T Cells
5%
Improved Outcomes
5%
Durable Remission
5%
Medicine and Dentistry
T Cell
65%
Chimeric Antigen Receptor T-Cell
55%
Chimeric Antigen Receptor
32%
Neoplasm
25%
Chimeric Antigen Receptor T-Cell Immunotherapy
22%
Immunotherapy
22%
Malignant Neoplasm
21%
Cell Therapy
20%
Disease
20%
Chimeric Antigen Receptor Immunotherapy
19%
B Cell
17%
Ganglioneuroblastoma
16%
Cancer
15%
Acute Lymphoblastic Leukemia
13%
Clinical Trial
10%
B-Cell Chronic Lymphocytic Leukemia
8%
B-Cell Lymphoma
7%
Solid Malignant Neoplasm
7%
Pediatrics
7%
Childhood Cancer
7%
Cytotoxicity
6%
Hematologic Malignancy
6%
Leukemia
6%
Ovarian Cancer
6%
Cell Transplantation
6%
Hematopoietic Cell
6%
Immunity
5%
Xenograft
5%
Death Receptor
5%
Immunology and Microbiology
T Cell
48%
Chimeric Antigen Receptor T-Cell
39%
Chimeric Antigen Receptor
38%
Immunotherapy
19%
CD19
11%
B Cell
10%
CD22
9%
Chimeric Antigen Receptor T-Cell Therapy
8%
Cell Function
7%
Immunity
7%
Cytotoxicity
6%
Antigen Specificity
5%
T Cell Receptor
5%